BACKGROUND: Dyslipidemia is common in the morbidly obese population. A previous study from our institution demonstrated improved lipid parameters 1 and 2 years after laparoscopic Roux-en-Y gastric bypass (LRYGB) with fewer patients taking lipid-modifying medications postoperatively, suggesting cost-savings over time. Our objective was to evaluate lipid parameters and lipid-modifying medication use at 5 years postoperative. METHODS: The medical records of patients who underwent LRYGB from September 2001 through July 2008 were reviewed. Inclusion criteria consisted of both preoperative and 5-year postoperative lipid values available. RESULTS: Six hundred eighty-two patients underwent LRYGB during the study period; 450 had data available at 5 years postoperative, and 187 patients met the inclusion criteria. Mean age was 46.3 years, and 83 % were women. Mean preoperative body mass index was 47.4 kg/m(2). Total cholesterol was 191.2 ± 35.4 preoperatively and 181.1 ± 33.0 at 5 years postoperative (P = 0.003). Low-density lipoprotein (LDL) was 107.9 ± 30.9 preoperatively and 95.3 ± 29.7 at 5 years postoperative (P < 0.001). High-density lipoprotein (HDL) was 48.7 ± 12.8 preoperatively and 65.1 ± 18.0 at 5 years postoperative (P < 0.001). Triglycerides were 171.3 ± 78.6 preoperatively and 112.9 ± 60.7 5 years postoperative (P < 0.001). Preoperatively, 35 % of patients were on lipid-modifying medications, and at 5 years postoperatively, 26 % required lipid-modifying medications (P = 0.002). CONCLUSIONS: Patients who have undergone LRYGB continue to show favorable change in their lipid profiles at 5 years postoperative. Furthermore, fewer patients were taking lipid-modifying medications at 5 years postoperatively than preoperatively.
BACKGROUND:Dyslipidemia is common in the morbidly obese population. A previous study from our institution demonstrated improved lipid parameters 1 and 2 years after laparoscopic Roux-en-Y gastric bypass (LRYGB) with fewer patients taking lipid-modifying medications postoperatively, suggesting cost-savings over time. Our objective was to evaluate lipid parameters and lipid-modifying medication use at 5 years postoperative. METHODS: The medical records of patients who underwent LRYGB from September 2001 through July 2008 were reviewed. Inclusion criteria consisted of both preoperative and 5-year postoperative lipid values available. RESULTS: Six hundred eighty-two patients underwent LRYGB during the study period; 450 had data available at 5 years postoperative, and 187 patients met the inclusion criteria. Mean age was 46.3 years, and 83 % were women. Mean preoperative body mass index was 47.4 kg/m(2). Total cholesterol was 191.2 ± 35.4 preoperatively and 181.1 ± 33.0 at 5 years postoperative (P = 0.003). Low-density lipoprotein (LDL) was 107.9 ± 30.9 preoperatively and 95.3 ± 29.7 at 5 years postoperative (P < 0.001). High-density lipoprotein (HDL) was 48.7 ± 12.8 preoperatively and 65.1 ± 18.0 at 5 years postoperative (P < 0.001). Triglycerides were 171.3 ± 78.6 preoperatively and 112.9 ± 60.7 5 years postoperative (P < 0.001). Preoperatively, 35 % of patients were on lipid-modifying medications, and at 5 years postoperatively, 26 % required lipid-modifying medications (P = 0.002). CONCLUSIONS:Patients who have undergone LRYGB continue to show favorable change in their lipid profiles at 5 years postoperative. Furthermore, fewer patients were taking lipid-modifying medications at 5 years postoperatively than preoperatively.
Authors: Lars Sjöström; Anna-Karin Lindroos; Markku Peltonen; Jarl Torgerson; Claude Bouchard; Björn Carlsson; Sven Dahlgren; Bo Larsson; Kristina Narbro; Carl David Sjöström; Marianne Sullivan; Hans Wedel Journal: N Engl J Med Date: 2004-12-23 Impact factor: 91.245
Authors: Ninh T Nguyen; Esteban Varela; Allen Sabio; Cam-Ly Tran; Michael Stamos; Samuel E Wilson Journal: J Am Coll Surg Date: 2006-05-30 Impact factor: 6.113
Authors: Paul Poirier; Marc-André Cornier; Theodore Mazzone; Sasha Stiles; Susan Cummings; Samuel Klein; Peter A McCullough; Christine Ren Fielding; Barry A Franklin Journal: Circulation Date: 2011-03-14 Impact factor: 29.690
Authors: Judith Hsia; Rebecca Rodabough; Milagros C Rosal; Barbara Cochrane; Barbara V Howard; Linda Snetselaar; William H Frishman; Marcia L Stefanick Journal: Am J Med Date: 2002-10-01 Impact factor: 4.965
Authors: Ted D Adams; Lance E Davidson; Sheldon E Litwin; Ronette L Kolotkin; Michael J LaMonte; Robert C Pendleton; Michael B Strong; Russell Vinik; Nathan A Wanner; Paul N Hopkins; Richard E Gress; James M Walker; Tom V Cloward; R Tom Nuttall; Ahmad Hammoud; Jessica L J Greenwood; Ross D Crosby; Rodrick McKinlay; Steven C Simper; Sherman C Smith; Steven C Hunt Journal: JAMA Date: 2012-09-19 Impact factor: 56.272
Authors: F M Sacks; M A Pfeffer; L A Moye; J L Rouleau; J D Rutherford; T G Cole; L Brown; J W Warnica; J M Arnold; C C Wun; B R Davis; E Braunwald Journal: N Engl J Med Date: 1996-10-03 Impact factor: 91.245
Authors: David Arterburn; Daniel P Schauer; Ruth E Wise; Keith S Gersin; David R Fischer; Calvin A Selwyn; Anne Erisman; Joel Tsevat Journal: Obes Surg Date: 2008-08-13 Impact factor: 4.129
Authors: Daniel Gero; Lucie Favre; Pierre Allemann; Pierre Fournier; Nicolas Demartines; Michel Suter Journal: Obes Surg Date: 2018-03 Impact factor: 4.129